Illumina-Grail deal draws in-depth EU review

By Natalie McNelis ( July 22, 2021, 16:16 GMT | Insight) -- Illumina’s $8 billion bid to buy cancer-testing start up Grail will face an in-depth investigation, the European Commission said today, citing concerns that the deal may reduce competition and innovation in the emerging market for cancer-detection tests based on sequencing technologies. The commission now has until Nov. 29 to reach a decision on the deal.Illumina’s $8 billion bid to buy cancer-testing start up Grail will face an in-depth investigation, the European Commission said today....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Prepare for tomorrow’s regulatory change, today

Related Sections